Merck Could Strike 30 Billion Deal for Revolution Medicines
oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]
AI Summary: Merck is reportedly in advanced talks to acquire Revolution Medicines—a Redwood City–based cancer drug developer—in a deal that could be worth around $30 billion. A separate report adds speculative color, reinforcing market buzz about this strategic move in oncology.
New Jersey system to join RWJBarnabas
Kristin Kuchno / beckershospitalreview - West Orange, N.J.-based RWJBarnabas Health and Englewood (N.J.) Health have signed a definitive agreement under which Englewood would become part of RWJBarnabas Health. The transaction is subject to state and federal regulatory approvals, according to a J…
AI Summary: A definitive agreement has been reached for Englewood Health to become part of West Orange–based RWJBarnabas Health, signaling a major consolidation in the New Jersey market. The merger is expected to drive significant investment in regional hospital networks and overcome previous regulatory hurdles, marking a new phase in local healthcare integration.
Maimonides Health to merge with NYC Health + Hospitals supported by $2.2B state grant
fiercehealthcare - Brooklyn, New York-based Maimonides Health is merging with New York City's public health system NYC Health + Hospitals, the organizations announced Monday.
AI Summary: Brooklyn-based Maimonides Health is merging with New York City’s public health system, bolstered by a $2.2 billion state grant. The integration is expected to streamline services and strengthen healthcare delivery in the region, ultimately broadening patient access and improving community care.
AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer
Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...
AI Summary: Reports indicate that AstraZeneca has struck a global licensing agreement with Jacobio Pharma for its investigational pan‑KRAS inhibitor. With a deal value of up to $2 billion and an upfront commitment, the move is set to reinforce AstraZeneca’s oncology pipeline with next‑generation targeted therapy.
Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug
Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...
AI Summary: Two separate reports confirm that Sanofi has completed a $2.2 billion deal to acquire Dynavax Technologies. This strategic move strengthens Sanofi’s vaccine lineup by adding a commercially proven hepatitis B vaccine and a clinical‐stage shingles candidate, positioning the company for enhanced market competitiveness amid global pressures.
ChristianaCare, Virtua Health call off $6.3B merger plans
fiercehealthcare - ChristianaCare and Virtua Health have pulled the plug on their merger plans, jettisoning a deal that would have created a health system with a combined $6.3 billion in annual revenue.
AI Summary: Providers ChristianaCare and Virtua Health have abruptly halted merger discussions for a deal valued at $6.3 billion. Officials argue that operating independently will better serve their local communities, even if joining forces might have promised a blockbuster scale – proving once again that sometimes size isn’t everything.
Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resigns
Alex Hoffman / endpoints - → In what appears to be another blow to Novo Nordisk, ex-Pfizer CSO Mikael Dolsten has withdrawn his nomination to join the company's board of directors due to ...
AI Summary: Merck has made a blockbuster move by finalizing a $9.2 billion deal to acquire Cidara Therapeutics’ late‐stage anti‐influenza candidate. This acquisition underscores Merck’s commitment to expanding its antiviral portfolio and marks a key strategic investment in advancing flu prevention amid evolving global health threats.
Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera
Frank Vinluan / medcitynews - Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo Nordisk was willing to pay. The financial consideration and the greater certainly of a deal close tipped the balance in Pfizer’s favo…
AI Summary: In a dramatic showdown over obesity biotech firm Metsera, Pfizer’s up-to-$10B cash offer edged out Novo Nordisk’s bid. The fiercely competitive deal highlights the high stakes and intense market focus on innovative therapeutics in obesity management.
Pfizer poised to buy Metsera in $10 bn deal after bidding war
medicalxpress - Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's board and Danish challenger Novo Nordisk called a halt to a back-and-forth bidding war.
AI Summary: In a dramatic bidding war for a promising biotech startup, Pfizer’s improved $10 billion offer prevailed—until Novo Nordisk raised its bid yet again. This high-stakes takeover tussle underscores the fierce competition and strategic importance of emerging therapies.